טוען...
The Risks of miRNA Therapeutics: In a Drug Target Perspective
RNAi therapeutics have been growing. Patisiran and givosiran, two siRNA-based drugs, were approved by the Food and Drug Administration in 2018 and 2019, respectively. However, there is rare news on the advance of miRNA drugs (another therapeutic similar to siRNA drug). Here we report the existing ob...
שמור ב:
| הוצא לאור ב: | Drug Des Devel Ther |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Dove
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7910153/ https://ncbi.nlm.nih.gov/pubmed/33654378 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S288859 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|